Molecular pathogenesis of retinal and choroidal vascular diseases

Age-Related Eye Disease Study Research Group, 2001, A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss, Arch. Ophthalmol., 119, 1417, 10.1001/archopht.119.10.1417

Aiello, 1995, Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins, Proc. Natl. Acad. Sci. USA, 92, 10457, 10.1073/pnas.92.23.10457

Alon, 1995, Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity, Nat. Med., 1, 1024, 10.1038/nm1095-1024

Auricchio, 2002, Inhibition of retinal neovascularization by intraocular viral-mediated delivery of anti-angiogenic agents, Mol. Ther., 6, 490, 10.1006/mthe.2002.0702

Avery, 2014, Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD, Br. J. Ophthalmol., 98, 1543, 10.1136/bjophthalmol-2014-305252

Bainbridge, 2002, Inhibition of retinal neovascularization by gene transfer of soluble VEGF receptor sFlt-1, Gene Ther., 9, 320, 10.1038/sj.gt.3301680

Balaggan, 2006, EIAV vector-mediated delivery of endostatin or angiostatin inhibits angiogenesis and vascular hyperpermeability in experimental CNV, Gene Ther., 13, 1153, 10.1038/sj.gt.3302769

Barleon, 1996, Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1, Blood, 87, 3336, 10.1182/blood.V87.8.3336.bloodjournal8783336

Betsholtz, 2004, Insight into the physiological functions of PDGF through genetic studies in mice, Cytokine Growth Factor Rev., 15, 215, 10.1016/j.cytogfr.2004.03.005

Boyer, 2009, Combined inhibition of platelet-derived (PDGF) and vascular endothelial (VEGF) growth factors for the treatment of neovascular age-related macular degeneration (NV-AMD). Results of a phase 1 study, Invest. Ophthalmol. Vis. Sci., 50

Brown, 2006, Ranibizumab versus verteporfin for neovascular age-related macular degeneration, N. Eng. J. Med., 355, 1432, 10.1056/NEJMoa062655

Brown, 2010, Efficacy and safety of ranibizumab in the treatment of macular edema secondary to central retinal vein occlusion:6-month results of the phase III CRUISE study, Ophthalmology, 117, 1124, 10.1016/j.ophtha.2010.02.022

Brown, 2011, Sustained benefits from ranibizumab for macular edema following branch retinal vein occlusion: 12-month outcomes of a phase III study, Ophthalmology, 118, 1594, 10.1016/j.ophtha.2011.02.022

Campochiaro, 2004, Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412, Invest. Ophthalmol. Vis. Sci., 45, 922, 10.1167/iovs.03-0955

Campochiaro, 2006, Ocular versus extraocular neovascularization: mirror images or vague resemblances, Invest. Ophthalmol. Vis. Sci., 47, 462, 10.1167/iovs.05-1494

Campochiaro, 1993, Corneal endothelial cell matrix promotes expression of differentiated features of retinal pigmented epithelial cells: implication of laminin and basic fibroblast growth factor as active components, Exp. Eye Res., 57, 537, 10.1006/exer.1993.1158

Campochiaro, 2006, Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial, Hum. Gene Ther., 17, 167, 10.1089/hum.2006.17.167

Campochiaro, 2008, Ranibizumab for macular edema due to retinal vein occlusions; implication of VEGF as a critical stimulator, Molec. Ther., 16, 791, 10.1038/mt.2008.10

Campochiaro, 2010, Ranibizumab for macular edema following branch retinal vein occlusion: 6-month primary endpoint results of a phase III study, Ophthalmology, 117, 1102, 10.1016/j.ophtha.2010.02.021

Campochiaro, 2011, Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: 12-month outcomes of a phase III study, Ophthalmology, 118, 2041, 10.1016/j.ophtha.2011.02.038

Campochiaro, 2011, Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema, Ophthalmology, 118, 626, 10.1016/j.ophtha.2010.12.028

Campochiaro, 2012, Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema, Ophthalmology, 119, 2125, 10.1016/j.ophtha.2012.04.030

Campochiaro, 2013, Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion, Ophthalmology, 120, 795, 10.1016/j.ophtha.2012.09.032

Campochiaro, 2014, Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients iwth diabetic macular edema, Ophthalmology, 121, 1783, 10.1016/j.ophtha.2014.03.021

Campochiaro, 2015, Treatment of diabetic macular edema with an inhibitor of vascular endothelial-protein tyrosine phosphatase that activates Tie2, Ophthalmology, 122, 545, 10.1016/j.ophtha.2014.09.023

Channa, 2015, Regression of choroidal neovascularization results in macular atrophy in anti-vascular endothelial growth factor-treated eyes, Am. J. Ophthalmol., 159, 9, 10.1016/j.ajo.2014.09.012

Davis, 1995, A human retinal pigment epithelial cell line that retains epithelial characteristics after prolonged culture, Invest. Ophthalmol. Vis. Sci., 36, 955

Davis, 1996, Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning, Cell, 87, 1161, 10.1016/S0092-8674(00)81812-7

Dawson, 1999, Pigment epithelium-derived factor: a potent inhibitor of angiogenesis, Science, 285, 245, 10.1126/science.285.5425.245

Dobi, 1989, A new model of choroidal neovascularization in the rat, Arch. Ophthalmol., 107, 264, 10.1001/archopht.1989.01070010270035

Dong, 2014, Antagonism of PDGF-BB suppresses subretinal neovascularization and enhances the effects of blocking VEGF-A, Angiogenesis, 17, 553

Elice, 2009, Thrombosis associated with angiogenesis inhibitors, Best. Pract. Res. Clin. Haematol., 22, 115, 10.1016/j.beha.2009.01.001

Eremina, 2008, VEGF inhibition and renal thrombotic microangiopathy, N. Engl. J. Med., 358, 1129, 10.1056/NEJMoa0707330

Fachinger, 1999, Functional interaction of vascular endothelial-protein-tyrosine phosphatase with the angiopoietin receptor Tie-2, Oncogene, 18, 5943, 10.1038/sj.onc.1202992

Fukai, 2002, Lack of collagen XVIII/endostatin results in eye abnormalities, EMBO J., 21, 1535, 10.1093/emboj/21.7.1535

Gale, 2002, Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by angiopoietin-1, Devel. Cell., 3, 411, 10.1016/S1534-5807(02)00217-4

Grunwald, 2012, Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials, Ophthalmology, 121, 150, 10.1016/j.ophtha.2013.08.015

Hackett, 2000, Angiopoietin 2 expression in the retina: upregulation during physiologic and pathologic neovascularization, J. Cell. Physiol., 184, 275, 10.1002/1097-4652(200009)184:3<275::AID-JCP1>3.0.CO;2-7

Hackett, 2002, Angiopoietin-2 plays an important role in retinal angiogenesis, J. Cell. Physiol., 192, 182, 10.1002/jcp.10128

Heier, 2012, Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration, Ophthalmology, 119, 2537, 10.1016/j.ophtha.2012.09.006

Honda, 2000, Experimental subretinal neovascularization is inhibited by adenovirus-mediated soluble VEGF.flt-1 receptor gene transfection: a role of VEGF and possible treatment for SRN in age-related macular degeneration, Gene Ther., 7, 978, 10.1038/sj.gt.3301203

Igarashi, 2003, Lentivirus-mediated expression of angiostatin efficiently inhibits neovascularization in a murine proliferative retinopathy model, Gene Ther., 10, 219, 10.1038/sj.gt.3301878

Inai, 2004, Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts, Am. J. Pathol., 165, 35, 10.1016/S0002-9440(10)63273-7

Iwase, 2013, Sustained delivery of a HIF-1 antagonist for ocular neovascularization, J. Control. Release, 172, 625, 10.1016/j.jconrel.2013.10.008

Kachi, 2008, EIAV vector-mediated co-delivery of endostatin and angiostatin driven by the RPE-specific VMD2 promoter inhibits choroidal neovascularization, Hum. Gene Ther., 20, 31, 10.1089/hum.2008.046

Kamba, 2005, VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature, Am. J. Physiol. Heart Circ. Physiol., 290, H560, 10.1152/ajpheart.00133.2005

Kelly, 2003, Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1, Circ. Res., 93, 1074, 10.1161/01.RES.0000102937.50486.1B

Kim, 2000, Angiopoietin-1 regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway, Circ. Res., 86, 24, 10.1161/01.RES.86.1.24

Kim, 2000, Angiopoietin-2 at high concentration can enhance endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway, Oncogene, 19, 4549, 10.1038/sj.onc.1203800

Klein, 2008, Retinal precursors and the development of geographic atrophy in age-related macular degeneration, Ophthalmology, 115, 1026, 10.1016/j.ophtha.2007.08.030

Krueger, 1990, Structural diversity and evolution of human receptor-like protein tyrosine phosphatases, EMBO J., 9, 3241, 10.1002/j.1460-2075.1990.tb07523.x

Kryzstolik, 2002, Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment, Arch. Ophthalmol., 120, 338, 10.1001/archopht.120.3.338

Kurihara, 2012, Targeted deletion of Vegfa in adult mice induces vision loss, J. Clin. Invest, 122, 4117, 10.1172/JCI65157

Kwak, 2000, VEGF is an important stimulator in a model of choroidal neovascularization, Invest. Ophthalmol. Vis. Sci., 41, 3158

Lai, 2001, Suppression of choroidal neovascularization by adeno-associated virus vector expressing angiostatin, Invest. Ophthalmol. Vis. Sci., 42, 2401

Lai, 2002, Potential long-term inhibition of ocular neovascularization by recombinant adeno-associated virus-mediated secretion gene therapy, Gene Ther., 9, 804, 10.1038/sj.gt.3301695

Lai, 2005, Long-term evaluation of AAV-mediated sFlt-1 gene therapy for ocular neovascularization in mice and monkeys, Mol. Ther., 12, 659, 10.1016/j.ymthe.2005.04.022

Lee, 2009, Antracycline chemotherapy inhibits HIF-1 transcriptional activity and tumor induced mobilizatio of circulating angiogenic cells, Proc. Natl. Acad. Sci. USA, 106, 2353, 10.1073/pnas.0812801106

Lima e Silva, 2007, The SDF-1/CXCR4 ligand/receptor pair is an important contributor to several types of ocular neovascularization, FASEB J., 21, 3219, 10.1096/fj.06-7359com

Lindahl, 1997, Pericyte loss and microaneurysm formation in PDGF-B-deficient mice, Science, 277, 242, 10.1126/science.277.5323.242

Lindblom, 2003, Endothelial PDGF-B retention is required for proper investment of pericytes in the microvessel wall, Genes Dev., 17, 1835, 10.1101/gad.266803

Lukason, 2011, Inhibition of choroidal neovascularization in a nonhuman primate model by intravitreal administration of an AAV2 vector expressing a novel anti-VEGF molecule, 19, 260

Maisonpierre, 1997, Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis, Science, 277, 55, 10.1126/science.277.5322.55

Mameros, 2005, Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function, Am. J. Pathol., 167, 1451, 10.1016/S0002-9440(10)61231-X

Mori, 2001, Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin, Am. J. Pathol., 159, 313, 10.1016/S0002-9440(10)61697-5

Mori, 2001, Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization, J. Cell. Physiol., 188, 253, 10.1002/jcp.1114

Mori, 2001, Regression of ocular neovascularization by increased expression of pigment epithelium-derived factor, Invest. Ophthalmol. Vis. Sci., 43, 2428

Mori, 2002, Retina-specific expression of PDGF-B versus PDGF-A: vascular versus nonvascular proliferative retinopathy, Invest. Ophthalmol. Vis. Sci., 43, 2001

Mori, 2002, AAV-mediated gene transfer of pigment epithelium-derived factor inhibits choroidal neovascularization, Invest. Ophthalmol. Vis. Sci., 43, 1994

Mousa, 1999, Extracellular matrix-integrin binding modulates secretion of angiogenic growth factors by retinal pigmented epithelial cells, J. Cell. Biochem., 74, 135, 10.1002/(SICI)1097-4644(19990701)74:1<135::AID-JCB15>3.0.CO;2-#

Nambu, 2004, Angiopoietin 1 inhibits ocular neovascularization and breakdown of the blood-retinal barrier, Gene Ther., 11, 865, 10.1038/sj.gt.3302230

Nambu, 2005, Angiopoietin 1 prevents retinal detachment in an aggressive model of proliferative retinopathy, but has no effect on established neovascularization, J. Cell. Physiol., 204, 227, 10.1002/jcp.20292

Nguyen, 2003, Supplemental inspired oxygen improves diabetic macular edema; a pilot study, Invest. Ophthalmol. Vis. Sci., 45, 617, 10.1167/iovs.03-0557

Nguyen, 2006, Vascular endothelial growth factor is a critical stimulus for diabetic macular edema, Am. J. Ophthalmol., 142, 961, 10.1016/j.ajo.2006.06.068

Nguyen, 2009, Primary end point (six months) results of the ranibizumab for edema of the macula in diabetes (READ-2) study, Ophthalmology, 116, 2175, 10.1016/j.ophtha.2009.04.023

Nguyen, 2012, Ranibizumab for diabetic macular edema. Results from 2 phase III randomized Trials: RISE and RIDE, Ophthalmology, 119, 789, 10.1016/j.ophtha.2011.12.039

O'Reilly, 1994, Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma, Cell, 79, 315, 10.1016/0092-8674(94)90200-3

O'Reilly, 1997, Endostatin: an endogenous inhibitor of angiogenesis and tumor growth, Cell, 88, 277, 10.1016/S0092-8674(00)81848-6

Ohno-Matsui, 2002, Inducible expression of vascular endothelial growth factor in photoreceptors of adult mice causes severe proliferative retinopathy and retinal detachment, Am. J. Pathol., 160, 711, 10.1016/S0002-9440(10)64891-2

Okamoto, 1997, Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization, Am. J. Pathol., 151, 281

Oshima, 2004, Angiopoietin-2 enhances retinal vessel sensitivity to vascular endothelial growth factor, J. Cell. Physiol., 199, 412, 10.1002/jcp.10442

Oshima, 2004, Increased expression of VEGF in retinal pigmented epithelial cells is not sufficient to cause choroidal neovascularization, J. Cell. Physiol., 201, 393, 10.1002/jcp.20110

Oshima, 2004, Intraocular gutless adenoviral vectored VEGF stimulates anterior segment but not retinal neovascularization, J. Cell. Physiol., 199, 399, 10.1002/jcp.10441

Oshima, 2005, Different effects of angiopoietin 2 in different vascular beds in the eye; new vessels are most sensitive, FASEB J., 19, 963, 10.1096/fj.04-2209fje

Ozaki, 1997, Intravitreal sustained release of VEGF causes retinal neovascularization in rabbits and breakdown of the blood-retinal barrier in rabbits and primates, Exp. Eye Res., 64, 505, 10.1006/exer.1996.0239

Ozaki, 1999, Hypoxia inducible factor-1a is increased in ischemic retina: temporal and spatial correlation with VEGF expression, Invest. Ophthalmol. Vis. Sci., 40, 182

Ozaki, 2000, Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization, Am. J. Pathol., 156, 697, 10.1016/S0002-9440(10)64773-6

Park, 1994, Placenta growth factor: potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR, J. Biol. Chem., 269, 25646, 10.1016/S0021-9258(18)47298-5

Patz, 1953, Oxygen studies in retrolental fibroplasia: production of the microscopic changes of retrolental fibroplasia in experimental animals, Am. J. Ophthalmol., 36, 1511, 10.1016/0002-9394(53)91779-6

Pechan, 2009, Novel anit-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization, Gene Ther., 16, 10, 10.1038/gt.2008.115

Petitclerc, 2000, New functions for non-collagenous domains of human collagen type IV. Novel integrin ligands inhibiting angiogenesis and tumor growth in vivo, J. Biol. Chem., 275, 8051, 10.1074/jbc.275.11.8051

Pierce, 1996, Regulation of vascular endothelial growth factor by oxygen in a model of retinopathy of prematurity, Arch. Ophthalmol., 114, 1219, 10.1001/archopht.1996.01100140419009

Raisler, 2002, Adeno-associated virus type 2 expression of pigmented epithelium-derived factor or Kringles 1-3 of angiostatin reduce retinal neovascularization, Proc. Natl. Acad. Sci. USA, 99, 8909, 10.1073/pnas.122247299

Rosenfeld, 2006, Ranibizumab for neovascular age-related macular degeneration, N. Eng. J. Med., 355, 1419, 10.1056/NEJMoa054481

Rota, 2004, Marked inhibition of retinal neovascularization in rats following soluble-flt-1 gene transfer, J. Gene Med., 6, 992, 10.1002/jgm.586

Ryan, 1982, Subretinal neovascularization: natural history of an experimental model, Arch. Ophthalmol., 100, 1804, 10.1001/archopht.1982.01030040784015

Saint-Geniez, 2009, An essential role for RPE-derived soluble VEGF in the maintenance of the choriocapillaris, Proc. Natl. Acad. Sci. USA, 106, 18751, 10.1073/pnas.0905010106

Saishin, 2003, VEGF-TRAPR1R2 suppresses choroidal neovascularization and VEGF-induced breakdown of the blood-retinal barrier, J. Cell. Physiol., 195, 241, 10.1002/jcp.10246

Sato, 1995, Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation, Nature, 376, 70, 10.1038/376070a0

Semenza, 2000, HIF-1: mediator of physiological and pathophysiological responses to hypoxia, J. Appl. Physiol., 88, 1474, 10.1152/jappl.2000.88.4.1474

Seo, 2000, Photoreceptor-specific expression of PDGF-B results in traction retinal detachment, Am. J. Pathol., 157, 995, 10.1016/S0002-9440(10)64612-3

Shen, 2007, In vivo immunostaining demonstrates macrophages associate with growing and regressing vessels, Invest. Ophthalmol. Vis. Sci., 48, 4335, 10.1167/iovs.07-0113

Shen, 2014, Targeting VE-PTP activates TIE2 and stabilizes the ocular vasculature, J. Clin. Invest., 124, 4564, 10.1172/JCI74527

Smith, 1994, Oxygen-induced retinopathy in the mouse, Invest. Ophthalmol. Vis. Sci., 35, 101

Stone, 1995, Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia, J. Neurosci., 15, 4738, 10.1523/JNEUROSCI.15-07-04738.1995

Takahashi, 2003, Intraocular expression of endostatin reduces VEGF-induced retinal vascular permeability, neovascularization, and retinal detachment, FASEB J., 17, 896, 10.1096/fj.02-0824fje

The Diabetic Retinopathy Clinical Research Network, 2010, Randomized trial evaluating ranibzumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema, Ophthalmolgy, 117, 1064, 10.1016/j.ophtha.2010.02.031

Tobe, 1998, Evolution of neovascularization in mice with overexpression of vascular endothelial growth factor in photoreceptors, Invest. Ophthalmol. Vis. Sci., 39, 180

Tobe, 1998, Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model, Am. J. Pathol., 153, 1641, 10.1016/S0002-9440(10)65753-7

Tolentino, 1996, Vascular endothelial growth factor is sufficient to produce iris neovascularization and neovascular glaucoma in a nonhuman primate, Arch. Ophthalmol., 114, 964, 10.1001/archopht.1996.01100140172010

Ueno, 2008, Prolonged blockade of VEGF family members does not cause identifiable damage to retinal neurons or vessels, J. Cell. Physiol., 217, 13, 10.1002/jcp.21445

Umeda, 2006, Suppression and regression of choroidal neovascularization by systemic administration of an Alpha5Beta1 integrin antagonist, Mol. Pharmacol., 69, 1820, 10.1124/mol.105.020941

Vinores, 2006, Implication of the hypoxia response element of the VEGF promoter in mouse models of retinal and choroidal neovascularization, but not retinal vascular development, J. Cell. Physiol., 206, 749, 10.1002/jcp.20525

Weber, 1994, Mutations in the tissue inhibitor of metalloproteinases-3 (TIMP3) in patients with Sorsby's fundus dystrophy, Nat. Genet., 8, 352, 10.1038/ng1294-352

Yacyshyn, 2009, Tyrosine phosphatase beta regulates angiopoietin-Tie2 signaling in human endothelial cells, Angiogenesis, 12, 25, 10.1007/s10456-008-9126-0

Yamada, 1999, Hyperoxia causes decreased expression of vascular endothelial growth factor and endothelial cell apoptosis in adult retina, J. Cell. Physiol., 179, 149, 10.1002/(SICI)1097-4652(199905)179:2<149::AID-JCP5>3.0.CO;2-2

Yannuzzi, 2001, Retinal angiomatous proliferation in age-related macular degeneration, Retina, 21, 416, 10.1097/00006982-200110000-00003

Yoshida, 2010, Digoxin inhibits retinal ischemia-induced HIF-1alpha expression and ocular neovascularization, FASEB J., 24, 1759, 10.1096/fj.09-145664

Yu, 2000, Intraretinal oxygen levels before and after photoreceptor loss in the RCS rat, Invest. Ophthalmol. Vis. Sci., 41, 3999

Yuan, 2009, Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium, Molec. Cell. Biol., 29, 2011, 10.1128/MCB.01472-08

Zhang, 2008, Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth, Proc. Natl. Acad. Sci. USA, 105, 19579, 10.1073/pnas.0809763105